转移性复发和难治性神经母细胞瘤的合作方案(N-III-95)的结果。

Medical and pediatric oncology Pub Date : 2000-12-01 DOI:10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u

V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz

{"title":"转移性复发和难治性神经母细胞瘤的合作方案(N-III-95)的结果。","authors":"V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz","doi":"10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u","DOIUrl":null,"url":null,"abstract":"Background: Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.Procedure: Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.Results: Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.Conclusions: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.","PeriodicalId":18531,"journal":{"name":"Medical and pediatric oncology","volume":"35 6","pages":"724-6"},"PeriodicalIF":0.0000,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u","citationCount":"10","resultStr":"{\"title\":\"Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.\",\"authors\":\"V Castel, A Cañete, C Melero, T Acha, A Navajas, P García-Miguel, T Contra, J Molina, P Galarón, O Cruz\",\"doi\":\"10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.Procedure: Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.Results: Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.Conclusions: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.\",\"PeriodicalId\":18531,\"journal\":{\"name\":\"Medical and pediatric oncology\",\"volume\":\"35 6\",\"pages\":\"724-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical and pediatric oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical and pediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/1096-911x(20001201)35:6<724::aid-mpo53>3.0.co;2-u","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 10

摘要

背景:复发和难治性神经母细胞瘤的预后一致是致命的;需要新的治疗方法。方法:对复发和难治性神经母细胞瘤患者进行持续输注化疗联合MIBG治疗。结果:在4年多的时间里，登记了35例重度预处理患者，其中29例发生骨或/和骨髓转移。3级或4级血液学毒性经常发生，无中毒性死亡。16名患者有反应。5年总生存率为0.19。结论:该方法可行，毒性可控;它挽救了一些病人，延长了他们的生存时间。它值得用于新诊断的高危神经母细胞瘤患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.

Background: Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.

Procedure: Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.

Results: Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.

Conclusions: This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助